<DOC>
	<DOCNO>NCT00098891</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine MS-275 isotretinoin treat patient metastatic advance solid tumor lymphomas . MS-275 may stop growth cancer cell block enzymes necessary growth . Isotretinoin may help cancer cell develop normal cell . MS-275 may increase effectiveness isotretinoin make cancer cell sensitive drug . MS-275 isotretinoin may also stop growth solid tumor lymphomas stop blood flow cancer . Combining MS-275 isotretinoin may kill cancer cell</brief_summary>
	<brief_title>MS-275 Isotretinoin Treating Patients With Metastatic Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose MS-275 administer isotretinoin patient metastatic , progressive , refractory , unresectable solid tumor lymphomas . SECONDARY OBJECTIVES : I . Determine , preliminarily , tumor response patient treat regimen . II . Determine pharmacokinetic profile regimen patient . OUTLINE : This open-label , dose-escalation study MS-275 . Patients receive oral MS-275 day 1 , 8 , 15 oral isotretinoin twice daily day 1-21 . Courses repeat every 28 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos MS-275 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 12 patient treated MTD . Patients follow monthly .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Histologically confirm solid tumor lymphoma Metastatic , progressive , refractory , unresectable disease Not amenable standard curative measure No known brain metastasis Performance status ECOG 02 More 3 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hemoglobin &gt; 9 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN No suspect Gilbert 's syndrome Creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No unstable cardiac arryhthmia Able take retain oral medication No malabsorption problem No acute chronic gastrointestinal condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 1 month , , 3 month study treatment No known HIV positivity No weight loss &gt; 10 % within past 2 month No history allergic reaction attribute compound similar chemical biologic composition MS275 isotretinoin No uncontrolled illness No ongoing active infection No seizure disorder No psychiatric illness social situation would preclude study participation More 4 week since prior anticancer vaccine therapy More 4 week since prior anticancer immunotherapy No concurrent anticancer vaccine therapy No concurrent anticancer immunotherapy More 4 week since prior anticancer chemotherapy ( 6 week nitrosoureas , mitomycin , agent know cause prolong marrow supression ) No concurrent anticancer chemotherapy More 4 week since prior anticancer hormonal therapy except gonadotropinreleasing hormone ( GnRH ) agonist therapy noncastrated patient prostate cancer Concurrent GnRH agonist therapy noncastrated patient prostate cancer allow Concurrent luteinizing hormonereleasing hormone agonist therapy allow provided evidence tumor progression Concurrent adrenal steroid replacement therapy allow No concurrent ketoconazole secondline hormonal treatment prostate cancer No concurrent corticosteroid except treatment refractory nausea vomit No concurrent anticancer hormonal therapy More 4 week since prior anticancer radiotherapy More 2 week since prior palliative radiotherapy No concurrent anticancer radiotherapy More 4 week since prior major surgery Recovered prior therapy No prior MS275 No prior oral isotretinoin Isotretinoin treatment acne allow provide &gt; 3 year since prior administration More 4 week since prior anticancer therapy No concurrent tetracycline No concurrent highdose vitamin A No concurrent valproic acid No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>